pre-clinical data for c-terminus directed antibodies is not as good as for n-terminus directed antibodies targeting AB.
I personally don't think this is going to work. The strongest antibody candidate seems to be bapineuzumab. If it doesn't work, i don't think any of the other anti-amyloid candidates will (at least in Mild to moderate disease)